FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3114565741> ?p ?o ?g. }

• W3114565741 endingPage "296" @default.
• W3114565741 startingPage "290" @default.
• W3114565741 abstract "Long-term glycemic control reduces retinopathy risk, but transient worsening can occur with glucose control intensification. Glucagon-like peptide 1 receptor agonists (GLP-1RA) lower glucose, but the long-term impact on retinopathy is unknown. GLP-1RA cardiovascular outcome trials (CVOTs) provide long-term follow-up, allowing examination of retinopathy outcomes.To examine the associations between retinopathy, HbA1c, systolic blood pressure (SBP), and weight in GLP-1RA CVOTs.Systematic review identified six placebo-controlled GLP-1RA CVOTs reporting prespecified retinopathy outcomes.Published trial reports were used as the primary data sources.HbA1c, SBP, and weight data throughout follow-up by treatment group were extracted.Random-effects model meta-analysis showed no association between GLP-1RA treatment and retinopathy (odds ratio [OR] 1.10; 95% CI 0.93, 1.30), with high heterogeneity between studies (I2 = 52.2%; Q statistic P = 0.063). Univariate meta-regression showed an association between retinopathy and average HbA1c reduction during the overall follow-up (slope = 0.77, P = 0.007), but no relationship for SBP or weight. Sensitivity analyses for HbA1c showed a relationship at 3 months (P = 0.006) and 1 year (P = 0.002). A 0.1% (1.09 mmol/mol) increase in HbA1c reduction was associated with 6%, 14%, or 8% increased Ln(OR) for retinopathy at the 3-month, 1-year, and overall follow-up, respectively.CVOTs were not powered to assess retinopathy outcomes and differed in retinopathy-related criteria and methodology. The median follow-up of 3.4 years is short compared with the onset of retinopathy.HbA1c reduction was significantly associated with increased retinopathy risk in meta-regression for GLP-1RA CVOTs. The magnitude of HbA1c reduction was correlated with retinopathy risk in people with diabetes and additional cardiovascular risk factors, but the long-term impact of improved glycemic control on retinopathy was unmeasured in these studies. Retinopathy status should be assessed when intensifying glucose-lowering therapy." @default.
• W3114565741 created "2021-01-05" @default.
• W3114565741 creator A5013408607 @default.
• W3114565741 creator A5024577116 @default.
• W3114565741 creator A5032554640 @default.
• W3114565741 creator A5038764606 @default.
• W3114565741 creator A5055443598 @default.
• W3114565741 creator A5065924611 @default.
• W3114565741 date "2020-12-14" @default.
• W3114565741 modified "2023-10-03" @default.
• W3114565741 title "HbA1c Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression" @default.
• W3114565741 cites W1963755948 @default.
• W3114565741 cites W1966206262 @default.
• W3114565741 cites W2054981500 @default.
• W3114565741 cites W2057986301 @default.
• W3114565741 cites W2100972808 @default.
• W3114565741 cites W2116484301 @default.
• W3114565741 cites W2138480916 @default.
• W3114565741 cites W2175077763 @default.
• W3114565741 cites W2302447233 @default.
• W3114565741 cites W2313488710 @default.
• W3114565741 cites W2337454357 @default.
• W3114565741 cites W2425644022 @default.
• W3114565741 cites W2437207291 @default.
• W3114565741 cites W2519510391 @default.
• W3114565741 cites W2597545061 @default.
• W3114565741 cites W2754041380 @default.
• W3114565741 cites W2886019047 @default.
• W3114565741 cites W2891332575 @default.
• W3114565741 cites W2894746763 @default.
• W3114565741 cites W2929228469 @default.
• W3114565741 cites W2948602156 @default.
• W3114565741 cites W2948612418 @default.
• W3114565741 cites W2989595227 @default.
• W3114565741 cites W3114565741 @default.
• W3114565741 cites W4206445899 @default.
• W3114565741 cites W4235291177 @default.
• W3114565741 cites W4245818898 @default.
• W3114565741 cites W4249650832 @default.
• W3114565741 doi "https://doi.org/10.2337/dc20-1815" @default.
• W3114565741 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7783944" @default.
• W3114565741 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33444163" @default.
• W3114565741 hasPublicationYear "2020" @default.
• W3114565741 type Work @default.
• W3114565741 sameAs 3114565741 @default.
• W3114565741 citedByCount "34" @default.
• W3114565741 countsByYear W31145657412020 @default.
• W3114565741 countsByYear W31145657412021 @default.
• W3114565741 countsByYear W31145657412022 @default.
• W3114565741 countsByYear W31145657412023 @default.
• W3114565741 crossrefType "journal-article" @default.
• W3114565741 hasAuthorship W3114565741A5013408607 @default.
• W3114565741 hasAuthorship W3114565741A5024577116 @default.
• W3114565741 hasAuthorship W3114565741A5032554640 @default.
• W3114565741 hasAuthorship W3114565741A5038764606 @default.
• W3114565741 hasAuthorship W3114565741A5055443598 @default.
• W3114565741 hasAuthorship W3114565741A5065924611 @default.
• W3114565741 hasBestOaLocation W31145657411 @default.
• W3114565741 hasConcept C126322002 @default.
• W3114565741 hasConcept C134018914 @default.
• W3114565741 hasConcept C156957248 @default.
• W3114565741 hasConcept C2777180221 @default.
• W3114565741 hasConcept C2778313320 @default.
• W3114565741 hasConcept C2779829184 @default.
• W3114565741 hasConcept C2780473172 @default.
• W3114565741 hasConcept C555293320 @default.
• W3114565741 hasConcept C71924100 @default.
• W3114565741 hasConcept C84393581 @default.
• W3114565741 hasConcept C95190672 @default.
• W3114565741 hasConceptScore W3114565741C126322002 @default.
• W3114565741 hasConceptScore W3114565741C134018914 @default.
• W3114565741 hasConceptScore W3114565741C156957248 @default.
• W3114565741 hasConceptScore W3114565741C2777180221 @default.
• W3114565741 hasConceptScore W3114565741C2778313320 @default.
• W3114565741 hasConceptScore W3114565741C2779829184 @default.
• W3114565741 hasConceptScore W3114565741C2780473172 @default.
• W3114565741 hasConceptScore W3114565741C555293320 @default.
• W3114565741 hasConceptScore W3114565741C71924100 @default.
• W3114565741 hasConceptScore W3114565741C84393581 @default.
• W3114565741 hasConceptScore W3114565741C95190672 @default.
• W3114565741 hasIssue "1" @default.
• W3114565741 hasLocation W31145657411 @default.
• W3114565741 hasLocation W31145657412 @default.
• W3114565741 hasLocation W31145657413 @default.
• W3114565741 hasLocation W31145657414 @default.
• W3114565741 hasLocation W31145657415 @default.
• W3114565741 hasOpenAccess W3114565741 @default.
• W3114565741 hasPrimaryLocation W31145657411 @default.
• W3114565741 hasRelatedWork W2150699126 @default.
• W3114565741 hasRelatedWork W2397162419 @default.
• W3114565741 hasRelatedWork W2401570230 @default.
• W3114565741 hasRelatedWork W2978619802 @default.
• W3114565741 hasRelatedWork W3161069591 @default.
• W3114565741 hasRelatedWork W3190746054 @default.
• W3114565741 hasRelatedWork W4297687594 @default.
• W3114565741 hasRelatedWork W2253550537 @default.
• W3114565741 hasRelatedWork W2612723704 @default.
• W3114565741 hasRelatedWork W943310924 @default.

• next